DMYD-B.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 10:42):

Stats
Today's Volume	350 653
Average Volume	255 015
Market Cap	1.01B
EPS	SEK0 ( 2023-10-11 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-8.06
ATR14	SEK0.0690 (0.62%)

Volume Correlation

Long: -0.02 (neutral)

Short: -0.88 (strong negative)

Signal:(56.921) Neutral

Diamyd Medical AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Diamyd Medical AB (publ) Correlation - Currency/Commodity

0.24
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.78
( moderate negative )

-0.03
( neutral )

-0.77
( moderate negative )

Diamyd Medical AB (publ) Financials

Annual	2023
Revenue:	SEK546 000
Gross Profit:	SEK-3.09M (-565.57 %)
EPS:	SEK-1.480

Q2	2024
Revenue:	SEK26 000.00
Gross Profit:	SEK-12.85M (-49 419.23 %)
EPS:	SEK-0.310

Q1	2024
Revenue:	SEK34 000.00
Gross Profit:	SEK-1.11M (-3 261.76 %)
EPS:	SEK-0.370

Q4	2023
Revenue:	SEK74 000.00
Gross Profit:	SEK-947 000 (-1 279.73 %)
EPS:	SEK-0.460

Financial Reports:

No articles found.

Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.